PL396313A1 - Allogeneic and autologous fibrin carrier, method for its preparation and the use of a fibrin carrier for transplantation of cells, especially human cells - Google Patents

Allogeneic and autologous fibrin carrier, method for its preparation and the use of a fibrin carrier for transplantation of cells, especially human cells

Info

Publication number
PL396313A1
PL396313A1 PL396313A PL39631311A PL396313A1 PL 396313 A1 PL396313 A1 PL 396313A1 PL 396313 A PL396313 A PL 396313A PL 39631311 A PL39631311 A PL 39631311A PL 396313 A1 PL396313 A1 PL 396313A1
Authority
PL
Poland
Prior art keywords
favorably
blood
platelet
plasma
fibrinogen
Prior art date
Application number
PL396313A
Other languages
Polish (pl)
Other versions
PL218235B1 (en
Inventor
Henryk Bursig
Stanisław Dyląg
Fabian Kępski
Dorota Król
Patrycja Sitek
Aleksandra Wysocka-Wycisk
Jolanta Żyła
Original Assignee
Regionalne Centrum Krwiodawstwa I Krwiolecznictwa
Henryk Bursig
Stanisław Dyląg
Fabian Kępski
Dorota Król
Patrycja Sitek
Aleksandra Wysocka-Wycisk
Jolanta Żyła
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regionalne Centrum Krwiodawstwa I Krwiolecznictwa, Henryk Bursig, Stanisław Dyląg, Fabian Kępski, Dorota Król, Patrycja Sitek, Aleksandra Wysocka-Wycisk, Jolanta Żyła filed Critical Regionalne Centrum Krwiodawstwa I Krwiolecznictwa
Priority to PL396313A priority Critical patent/PL218235B1/en
Priority to PCT/PL2012/000029 priority patent/WO2013039411A1/en
Publication of PL396313A1 publication Critical patent/PL396313A1/en
Publication of PL218235B1 publication Critical patent/PL218235B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14Macromolecular materials
    • A61L27/22Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/225Fibrin; Fibrinogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3616Blood, e.g. platelet-rich plasma
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

An autologous and allogenic fibrin carrier characterized in that it is a gel-like mixture of fibrinogen and platelet-rich plasma combined at a ratio 0.1-2 to 0.1 -2, favorably 1 : 1 of volume share, and a calcium chloride in a 0.1-99% solution, favorably a 10% solution at a ratio 0.1-2 to 0.1-2, favorably 1 : 1 relative to the mixture of fibrinogen and platelet-rich plasma. A method of obtaining an autologous fibrin carrier comprising blood collection, separation of blood plasma from blood cells, freezing and thawing of blood plasma, characterized in that the blood donation collected from the blood donor is separated from the concentrate of blood cells, i.e. erythrocytes, leukocytes being removed, said separation having the form of centrifugation at + 20 to + 24°C for 5 to 15 minutes, with centrifugation force of 700 to 2000 x g; afterwards plasma is pushed through to an empty satellite container, wherein centrifugation takes place at + 20°C to +24°C for 5-15 minutes at a centrifugation force of 2100 to 5000 x g to separate platelet-rich plasma, which is stored in bags, favorably breathable swinging bags for maximum 7 days and favorably 3 days. The remaining platelet-poor plasma is used for preparation of fibrinogen in cryoprecipitate, by freezing blood plasma twice to the temperature of -30°C to -90°C and thawing blood plasma at about + 4°C, for example in a water bath, then it is centrifuged at about + 4°C for 5-20 minutes at centrifugation force of 1000 to 5000 x g, wherein supernatant is removed and resultant cryoprecipitate is mixed with platelet-rich plasma from the container, at a ratio from 0.1 -2 to 0.1 -2, favorably 1 : 1, and with a calcium compound solution, favorably a 10% calcium chloride solution at a favorable ratio 1 : 1 relative to the mixture of fibrinogen and platelet-rich plasma. Use of an autologous fibrin carrier for obtaining a gel-like transplant, that is a carrier formed by mixing fibrinogen and platelet-rich plasma obtained from the recipient's blood, favorably of a single donation, or ready-made fibrinogen characterized by an adequate phenotype and platelet-rich plasma taken directly from the blood donation of the patient-recipient using the operating room's apparatus, wherein in the process of obtaining a carrier and prior to the addition of a 0.1%-99% calcium chloride solution at a ratio 0.1 -2 do 0.1-2, favorably 1 : 1 of volume share relative to the mixture of fibrinogen and platelet-rich plasma, from 5 thousand to 100 million recipient's cells or allogenic and xenogenic cells are added, cultured in a known way and processed on the transplantation's date by trypsinization, washing in a serum- containing medium and vitality assessment.
PL396313A 2011-09-12 2011-09-12 Allogeneic and autologous fibrin carrier, method for its preparation and the use of a fibrin carrier for transplantation of cells, especially human cells PL218235B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL396313A PL218235B1 (en) 2011-09-12 2011-09-12 Allogeneic and autologous fibrin carrier, method for its preparation and the use of a fibrin carrier for transplantation of cells, especially human cells
PCT/PL2012/000029 WO2013039411A1 (en) 2011-09-12 2012-04-30 Autologous and allogenic fibrin carrier, method of obtaining thereof and use of a fibrin carrier for transplantation of cells, particularly human cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL396313A PL218235B1 (en) 2011-09-12 2011-09-12 Allogeneic and autologous fibrin carrier, method for its preparation and the use of a fibrin carrier for transplantation of cells, especially human cells

Publications (2)

Publication Number Publication Date
PL396313A1 true PL396313A1 (en) 2013-03-18
PL218235B1 PL218235B1 (en) 2014-10-31

Family

ID=46229905

Family Applications (1)

Application Number Title Priority Date Filing Date
PL396313A PL218235B1 (en) 2011-09-12 2011-09-12 Allogeneic and autologous fibrin carrier, method for its preparation and the use of a fibrin carrier for transplantation of cells, especially human cells

Country Status (2)

Country Link
PL (1) PL218235B1 (en)
WO (1) WO2013039411A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL446279A1 (en) * 2023-09-30 2024-04-22 Keymed Spóła Z Ograniczoną Odpowiedzialnością Kit for producing an autologous dressing from blood, dressing, method of its production and its application

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL231230A0 (en) * 2014-02-27 2014-08-31 Omrix Biopharmaceuticals Ltd Fibrinogen formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL54175Y1 (en) 1992-10-01 1996-06-28 Tomasz Nowakowski Cake baking mould
US5674394A (en) * 1995-03-24 1997-10-07 Johnson & Johnson Medical, Inc. Single use system for preparation of autologous plasma
CN101053679B (en) * 2007-04-17 2010-05-26 浙江大学 Method for preparing polymer multiporous holder filled with fiber protein gel
CN101221186A (en) * 2007-12-14 2008-07-16 天津理工大学 Fibrin gel with protein recognition function and its preparing method
PL388247A1 (en) 2009-06-10 2010-12-20 Danuta Foicik Dispensing screw-cap

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL446279A1 (en) * 2023-09-30 2024-04-22 Keymed Spóła Z Ograniczoną Odpowiedzialnością Kit for producing an autologous dressing from blood, dressing, method of its production and its application

Also Published As

Publication number Publication date
WO2013039411A1 (en) 2013-03-21
PL218235B1 (en) 2014-10-31

Similar Documents

Publication Publication Date Title
Dessels et al. Making the switch: alternatives to fetal bovine serum for adipose-derived stromal cell expansion
CN105638642B (en) A kind of immunocyte frozen stock solution and its application
Schallmoser et al. Human platelet lysate can replace fetal bovine serum for clinical‐scale expansion of functional mesenchymal stromal cells
Bieback et al. Clinical protocols for the isolation and expansion of mesenchymal stromal cells
Gulliksson Defining the optimal storage conditions for the long-term storage of platelets
ES2880718T3 (en) Combined umbilical cord blood NK cells and their uses for the treatment of cancer and chronic infectious diseases
JP2009533059A5 (en)
WO2013111130A1 (en) A system and method for obtaining a cellular sample enriched with defined cells such as platelet rich plasma(prp)
Solomon et al. Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes: a strategy for GvHD prophylaxis in allogeneic PBSC transplantation
MY160835A (en) System for purifying certain cell populations in blood or bone marrow by depleting others
KR20220004086A (en) Systems and methods for extraction and cryopreservation of bone marrow
KR20110036644A (en) Method for controlling propagation of umbilical cord blood hematopoietic stem cells and use thereof
Antoninus et al. Human platelet lysate enhances the proliferation of Wharton's jelly-derived mesenchymal stem cells
GB2574333A (en) Method for the preparation and prolonged storage of growth factors and cytokines obtained from platelet rich plasma
US11589575B2 (en) Injectable preserving medium for preserving cells from placental blood, from bone marrow and from peripheral blood
CN102686725A (en) Expansion medium for CD34-negative stem cells
PL396313A1 (en) Allogeneic and autologous fibrin carrier, method for its preparation and the use of a fibrin carrier for transplantation of cells, especially human cells
CN107072189B (en) Composition for improving stability of stem cells
CN109423476A (en) It is used to prepare the kit of fat mesenchymal stem cell
US20220186187A1 (en) Compositions and methods for extraction of mesenchymal stem cells
WO2019100175A1 (en) Composition and method for the cultivation, expansion, preservation and/or pre-treatment of cells
CA2893828A1 (en) Point of care isolation and concentration of blood cells
Martinaud et al. In vitro characteristics of cryopreserved platelet concentrates reconstituted by fresh frozen or lyophilized plasma
Lee Clinical utilization of cord blood over human health: experience of stem cell transplantation and cell therapy using cord blood in Korea
CA2977202A1 (en) Improved photodynamic process and product obtained therefrom